Psyched Wellness Receives DTC EligibilityCybin Advances IND-Enabling Studies of Two Psychedelic Molecules, CYB003 and CYB004 for Investigational New Drug ApplicaRritual Appoints Sarton Molnar-Fenton, Vice President Sales USATryp Therapeutics Announces Listing on OTCQB and DTC EligibilityPure Extracts Dual Vertical Approach Incorporating Cannabis and Psychedelic Compounds Is Starting To Pay OffTryp Therapeutics Appoints Greg McKee as Chief Executive OfficerPsyence Group and Pure Extracts Sign JV Letter of Intent for the Extraction of Psilocybin from Psychedelic Mushrooms andCybin Announces Senior Management Changes to Lead Buildout of Development and Clinical Capabilities in the United StatesPsyched Wellness Initiates Study on AME-1 Extract for Gut HealthRritual Superfoods to Launch Product Line in Rite Aid Stores – Deep Dive: Tryp Therapeutics (CSE:TRYP)Cybin Signs Drug Development Agreement with Catalent for its Fast-Dissolve Formulation of Novel, Deuterated Tryptamine (Field Trip Has A Warchest Of Cash To Propel R&D and M&A Moving ForwardCybin Inc. Is Rapidly Progressing Its Drug Development Program With Plenty On The HorizonPure Extracts Orders Cutting Edge Vitalis Cosolvent Injection SystemTryp Therapeutics Announces Provisional Patent Filing For Improved Administration of PsychedelicsCybin Progresses Two Psychedelic Investigational New Drug (“IND”) Candidates and Announces Completion of Its 20th PrRritual Announces Successful Completion of Second Full Scale Manufacturing Run and Commencement of Third Full Scale ManuNuminus Wellness Is Taking Strides To Advance Its R&D Business UnitRritual Announces Successful Launch of US Facing E-Commerce Website and Provides Corporate Update

Numinus Wellness Is Making Major Headway On Its MDMA Trials

Feb 18, 2021 • 3:43 PM EST
2 MIN READ  •  By Michael Berger
Share Share - Facebook Share - Twitter

Last week, Numinus Wellness Inc. (TSXV: NUMI) reported a major development and we want to issue an update on the opportunity following this announcement.

The company is focused on creating an ecosystem of health solutions that are centered around the development of evidence-based psychedelic-assisted psychotherapies. Last week, Numinus announced that its MDMA compassionate access trial achieved significant progress toward treating patients with post-traumatic stress disorder (PTSD).

This trial is being pursued in collaboration with MAPS Public Benefit Corporation (MAPS PBC), a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), the leading developer of the treatment protocols, research and MDMA-assisted therapy training programs. Founded in 1986, MAPS is a 501(c)(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful use of psychedelics and cannabis.

When it comes to strategic relationships, we believe that MAPS represents one of the best potential partners and will monitor how the trial advances from here. Going forward, the companies will work to provide people who suffer from PTSD with more treatment options and we are favorable on this initiative.

This first-of-its-kind trial in Canada has successfully transitioned into the pre-implementation stage at Numinus’ Vancouver clinic. This follows the successful completion of several milestones and we are favorable on the track record of execution that Numinus is creating for itself. The company will be responsible for collecting safety data for Health Canada to further implement key research that supports individuals who are living with PTSD and have not benefited from existing treatment options.

A draft MDMA-assisted therapy protocol for PTSD has been adapted for the trial and it includes clear guidance surrounding necessary screening processes, patient health histories, as well as indications and potential contraindications before accepting participants. Initial regulatory meetings with Health Canada to define the trial’s implementation science strategy is complete and the next steps will include obtaining ethical and Health Canada approvals to allow for the recruitment of participants according to COVID-19 public health protocols.

During the last quarter, Numinus has been a strong performer and we will continue to monitor the opportunity. If you are interested in learning more about Numinus and MAPS, please send an email to with the subject “Numinus and MAPS” to be added to our distribution list.

Share Share - Facebook Share - Twitter


Authored By

Michael Berger


Get the Latest Cannabis News & Stock Picks.

Enter your email below to join the official Mushroomstocks newsletter.

 All good -- no spamming here.

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.